Who is sponsoring NCT04350801?

NCT04350801 is sponsored by Asan Medical Center.

What drugs are being tested in NCT04350801?

Interventions in NCT04350801: home-based cognitive monitoring.

What condition does NCT04350801 study?

NCT04350801 studies Mild Cognitive Impairment.

Is NCT04350801 still recruiting?

NCT04350801 is currently status unknown. Last updated 20 April 2020.

Last reviewed 2020-04-20 · How we verify

NCT04350801

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Home-based Cognitive Monitoring in MCI

Status unknown Last updated 20 April 2020

What this trial tests

trial testing home-based cognitive monitoring in Mild Cognitive Impairment in 40 participants. Status unknown.

Timeline

1 December 2019

Primary endpoint
1 November 2020

30 December 2020

Quick facts

Lead sponsor	Asan Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 December 2019
Primary completion	1 November 2020
Estimated completion	30 December 2020
Sites	1 location across South Korea

Drugs / interventions tested

home-based cognitive monitoring

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →

Sponsor

Asan Medical Center

Who can join

50 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04350801 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 20 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04350801.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing